Lacosamide Tablet
- All
- News
-
Glenmark Pharmaceuticals Gets Final US Approval For Lacosamide Tablet
Homegrown pharma major Glenmark Pharmaceuticals Ltd on Monday said it has received final approval from the US health regulator for its generic Lacosamide tablet, indicated for prevention and control of seizures.
-
Alembic Pharma Gets USFDA Nod For Seizures Treatment Drug
Alembic Pharma has received final approval from the US health regulator for Lacosamide tablets, used for treatment of partial-onset seizures, in the American market.
-
Aurobindo Gets US Nod For Seizures Treatment Drug
Aurobindo Pharma has received final approval from the US health regulator for its Lacosamide tablets used for treatment of partial-onset seizures in American market.
-
UCB files cases against Ranbaxy, Aurobindo, Glenmark, others
According to a petition filed by UCB Inc, UCB Pharma GMBH, Research Corporation Technologies, Inc and Harris FRC Corporation the patent of its drug Lacosamide Tablets, 50 mg, 100 mg, 150 mg and 200 mg would expire on March 17, 2022.
-
Glenmark Pharmaceuticals Gets Final US Approval For Lacosamide Tablet
Homegrown pharma major Glenmark Pharmaceuticals Ltd on Monday said it has received final approval from the US health regulator for its generic Lacosamide tablet, indicated for prevention and control of seizures.
-
Alembic Pharma Gets USFDA Nod For Seizures Treatment Drug
Alembic Pharma has received final approval from the US health regulator for Lacosamide tablets, used for treatment of partial-onset seizures, in the American market.
-
Aurobindo Gets US Nod For Seizures Treatment Drug
Aurobindo Pharma has received final approval from the US health regulator for its Lacosamide tablets used for treatment of partial-onset seizures in American market.
-
UCB files cases against Ranbaxy, Aurobindo, Glenmark, others
According to a petition filed by UCB Inc, UCB Pharma GMBH, Research Corporation Technologies, Inc and Harris FRC Corporation the patent of its drug Lacosamide Tablets, 50 mg, 100 mg, 150 mg and 200 mg would expire on March 17, 2022.
